Elotuzumab

證據等級: L5

預測適應症: 0 個

Elotuzumab: Multiple Myeloma — TxGNN Predictions Not Available

One-Sentence Summary

Elotuzumab (Empliciti) is a SLAMF7-targeting immunotherapy monoclonal antibody approved for the treatment of relapsed or refractory multiple myeloma in combination with lenalidomide or pomalidomide plus dexamethasone. The current Evidence Pack (v4, candidate TW-DB06317-multi) contains no TxGNN-predicted new indications for this drug, and two critical data gaps — mechanism of action detail and regulatory safety data — remain unresolved. A repurposing assessment cannot be completed with the information currently available; the recommended action is to hold pending data remediation.

Quick Overview

Item	Content
Original Indication	Multiple myeloma (relapsed/refractory) — in combination with lenalidomide + dexamethasone or pomalidomide + dexamethasone
Predicted New Indication	Not available — no TxGNN predictions in current Evidence Pack
TxGNN Prediction Score	Not available
Evidence Level	Unable to determine — no prediction output generated
Denmark Market Status	Not registered in queried national database
Number of Marketing Authorisations	0 (queried national database); EMA centralised authorisation exists separately
Recommended Decision	Hold

Why is This Prediction Reasonable?

This section normally provides mechanistic rationale for a TxGNN-predicted new indication. Because no predictions are available in this Evidence Pack, it instead documents the current state of knowledge about the drug to support future analysis.

Elotuzumab is a humanised IgG1 monoclonal antibody that targets SLAMF7 (Signaling Lymphocytic Activation Molecule Family member 7, also known as CS1/CRACC/CD319) — a glycoprotein highly expressed on multiple myeloma cells and natural killer (NK) cells. Its dual mechanism of action combines direct antibody-dependent cellular cytotoxicity (ADCC) through NK cell activation with direct opsonisation of malignant plasma cells, establishing it as a clinically validated immunotherapy in the multiple myeloma space.

The DrugBank query for DB06317 returned a successful result, confirming the drug record exists. However, detailed mechanism of action data was flagged as a High-severity data gap (DG002), meaning the structured MOA fields required for the mechanistic plausibility analysis were not populated. Separately, the regulatory safety data query — covering contraindications and package insert warnings — was flagged as a Blocking-severity data gap (DG001), preventing the standard safety pre-screen from being completed.

Without TxGNN prediction output, a formal repurposing hypothesis cannot be evaluated at this stage. From a biological standpoint, SLAMF7 expression has been reported in certain other haematological malignancies beyond myeloma (including some NK/T-cell lymphomas and Waldenström macroglobulinaemia), suggesting that repurposing potential may exist. Realising this potential, however, requires the model to produce ranked predictions and confidence scores before a structured assessment can proceed.

Denmark Market Information

No national marketing authorisations were found in the queried regulatory database (0 records; market status: not registered).

Important note for Danish prescribers: Elotuzumab is authorised in the European Union under the EMA centralised procedure as Empliciti (Bristol-Myers Squibb / AbbVie), approved since 2016. This centralised authorisation is valid in all EU/EEA member states including Denmark. The absence of records in the locally queried database reflects the data pipeline’s coverage, not a lack of legal authorisation. The EMA SmPC for Empliciti is the authoritative safety reference document.

Cytotoxicity

Elotuzumab is used exclusively in the treatment of multiple myeloma, a haematological malignancy. The cytotoxicity section applies.

Item	Content
Cytotoxicity Classification	Targeted immunotherapy — SLAMF7-directed humanised IgG1 monoclonal antibody
Myelosuppression Risk	Low for elotuzumab as a single agent; Moderate to High in standard combination regimens (lenalidomide + dexamethasone or pomalidomide + dexamethasone) due to the partner drugs
Emetogenicity Classification	Low
Monitoring Items	CBC with differential (to monitor for lenalidomide/pomalidomide-associated neutropenia and thrombocytopenia), liver function tests, infusion-related reaction monitoring (fever, chills, hypertension — most common during first infusion), lymphocyte counts
Handling Protection	Elotuzumab itself does not require cytotoxic handling precautions; combination partners lenalidomide and pomalidomide are teratogenic IMiDs subject to strict Pregnancy Prevention Programmes (PPP) — prescribers must comply with REVLIMID/IMNOVID REMS-equivalent EU risk management requirements

Safety Considerations

Both safety data fields (key warnings and contraindications) are flagged as unresolved data gaps in the current Evidence Pack, and no drug–drug interaction records were returned from the DDI query.

Please refer to the approved Summary of Product Characteristics (SmPC) for Empliciti (available via the EMA product page) for complete safety information, including infusion reaction management, infection risk, secondary malignancy monitoring, and embryo-foetal toxicity guidance specific to combination regimens.

Conclusion and Next Steps

Decision: Hold

Rationale: The Evidence Pack for Elotuzumab (DB06317) is currently incomplete in two critical areas: no TxGNN prediction output was generated, and both the mechanism of action detail and regulatory safety data are absent. Without a predicted indication to evaluate and without a safety pre-screen, a repurposing assessment cannot meet the minimum evidence threshold required to move forward.

To proceed, the following is needed:

TxGNN prediction output (Critical): Re-run the TxGNN model for DrugBank ID DB06317 to generate ranked predicted indications with confidence scores. Verify whether the multi suffix in the candidate ID (TW-DB06317-multi) indicates a known pipeline processing issue.
Mechanism of action data (High priority — DG002): Retrieve the structured MOA from the DrugBank API for DB06317, including pharmacological action, target proteins, and pathway associations.
Regulatory safety data (Blocking — DG001): Download and parse the EMA SmPC for Empliciti to populate warnings, contraindications, and special population guidance (renal/hepatic impairment, pregnancy).
EMA authorisation cross-reference: Map the EMA centralised marketing authorisation number for Empliciti into the Denmark market information section to provide an accurate regulatory landscape for Danish prescribers.
DDI data supplement: Retrieve drug–drug interaction data for elotuzumab in the context of its standard combination partners (lenalidomide, pomalidomide, dexamethasone, bortezomib) from a validated DDI resource (e.g., DrugBank interactions, SFINX, or Lexi-Interact).
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.